About Nocteva
From patient to treatment, seamlessly
Nocteva is a biotechnology company focused on accelerating therapeutic development for inherited rare diseases through advanced human organoid technology and translational research platforms. Our mission is to bridge the gap between fundamental research and clinical translation, through a seamless pipeline from patient to treatment.
Discuss your projectPatient
Patient-derived samples from clinical partners.
Reprogram
Reprogramming into patient-specific iPSCs.
Model
Disease-relevant organoid model generation.
Evaluate
Predictive, human-relevant preclinical data.
Translate
Accelerated path toward clinical development.
Next-generation organoid models, patient to platform
Nocteva builds organoid models from patient-derived cells, enabling disease research, drug discovery, and personalized medicine without animal testing.
Whether you require a single experimental platform or a complete end-to-end pipeline, our technologies can be tailored to your research questions and therapeutic goals.
Bridging the gap between fundamental research and clinical translation to advance safer, more effective, and more personalized therapies for inherited rare diseases.
Why researchers choose Nocteva
End-to-end under one roof
Access individual services or combine them into an integrated workflow, from iPSCs and organoids to sequencing, multi-omics and data analysis.
Rare-disease expertise
Specialized expertise in rare genetic diseases, combining disease biology, advanced models and molecular profiling.
Science you can build on
Rigorous, reproducible data generated by scientists and designed to support publication and further development.
Reinvesting our surplus into research
A share of Nocteva's own commercial surplus flows into the NRRF (Nocteva Research Reinvestment Fund) and goes directly back into research: both disease-focused work and the platform building (equipment, methods, and standardization) that makes that research possible and better, while strengthening capacity that can benefit many more rare diagnoses.
.png)
